Hanall Biopharma's Glucofree OR is back

Rename from Glucodown OR to Glucofree OR

Metformin OR 750mg Market supply and demand imbalance will be resolved

Metformin OR products, which had been suspended due to the detection of excess NDMA of carcinogenic substances, are returning.

 

Hanall Biopharma products have also returned to the reimbursed market with their names changed.

 

With the emergence of them, competition is expected to intensify as the imbalance in supply and demand of Metformin OR is resolved.

 

According to an industry on the 11th, Metformin OR products of Hanall Biopharma and Daewoong Bio have recently been lifted.

 

The items are Hanall Biopharmas Glucofree OR 500mg, Glucofree OR 750mg, and Daewoong Bio's Diaformin XR 500mg and Diaformin XR 750mg.

 

Hanall Biopharma's Glucofree OR is the name changed from Glucodown OR.

 

Glucodown OR was the second highest-selling product in the Metformin single-product market after the original Diabex (Daewoong Pharmaceutical).

 

In May 2020, manufacturing and sales of NDMA, a substance that is feared to cause cancer, were suspended because it exceeded the provisional management standards.

 

Hanall Biopharma has been able to lift its manufacturing and sales suspension by changing it to an impurity-free product for about two years.

 

Daewoong Bio's product, which was manufactured at the same factory and stopped manufacturing and selling together, has also returned.

 

With the re-launch of the two products, worries about supply and demand can be eased, especially in the Metformin OR 750mg market.

 

As the two products disappeared, Metformin OR 750mg was the only Metformin OR 750mg of Yuhan.

 

Since the suspension of sales in 2020, the demand for Metformin OR 750mg has increased rapidly, making it difficult to supply it.

 

45 items in the Metformin OR 500mg market receive benefits.

 

Hanall Biopharma and Daewoong Bio are also working to lift the suspension for 1000mg OR products.

 

Before the suspension in 2020, Hanall Biopharma was the only competitive drug for imported Glucophage XR 1000mg and Diabex XR 100mg for domestic brands.

 

Now, the number of competitive domestic drugs has increased as Dalim Biotech and Yuhan Corporation have newly entered.

 

Hanall Biopharma and Daewoong Bio are members of Daewoong Pharmaceutical Group.

 

Although Daewoong Pharmaceutical continues to rank No.

 

1 in the Metformin single-product market with its marketing import Diabex, its own production items of Hanall Biopharma and Daewoong Bio are also strategically important.

 

This is because it is necessary to maintain the overwhelming market share of Daewoong Pharmaceutical Group while being a domestically produced product that can check imported items.

 

Metformin preparation is the primary essential drug for patients with secondary diabetes.

 

As a result, it is expected that Yuhan and Dalim will compete fiercely with Hanall Biopharma and Daewoong Bio for the first place as they are growing high in the single market of Metformin after the suspension of sales.